We get numbers for diet .. how about intercourse?
Think you should contact BT by email and ask him to respond. He is the only one that can.
Alcobra Ltd. ( ADHD ) announced that it has started patient enrollment in a phase IIb study (n=60) on its lead candidate, metadoxine extended release (MDX). MDX is being developed for the treatment of fragile X syndrome.
The multi-center, randomized, placebo-controlled study will evaluate MDX for 6 weeks in adolescents and adults suffering from fragile X syndrome in comparison to placebo. Alcobra intends to complete the study and report top-line results from the same in the fourth quarter of this year.
The company stated in its press release that there are no approved products in the market for the treatment of fragile X syndrome. As a result, the approval of MDX will open up an untouched market for Alcobra.
We note that MDX is being developed for other indications as well. Alcobra is currently evaluating MDX in a phase III study for the treatment of adults suffering from attention deficit hyperactivity disorder. The company completed patient enrolment for the study last month.
Moreover, Alcobra is conducting a phase IIb study on MDX in pediatric attention deficit hyperactivity disorder. Alcobra expects top-line data from the study by the end of the year.
We are encouraged by the company's progress with MDX. Meanwhile, Shire ( SHPG ), among others, has a strong presence in the attention deficit hyperactivity disorder market. We expect investor focus to remain on MDX going forward.
ADHD develops new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. The lead drug candidate, Metadoxine Extended Release, or MDX, is studied throughout 4 different categories: MDX for adult ADHD, MDX for pediatric ADHD, MDX for Fragile X Syndrome and MDX for cognitive impairment.
Even though the stock of Alcobra Ltd was on the decline over the last week, there have been moments of significant uptrend since the beginning of the year, and we may see one again soon. Currently, the focus of investors is directed towards the data results from MDX for adult ADHD phase 3 clinical trials, which are expected to be reported September 30.
ADHD is a psychiatric disorder which causes significant problems of inattention, hyperactivity, or acting impulsively. The disorder usually starts at a young age, yet often persists into adolescence and adulthood. According to a research conducted by the Center for Disease Control, 9% of children in the U.S. suffer from ADHD and approximately 4-5% of adults worldwide are affected by it, yet most adults with ADHD remain untreated.
Alcobra Ltd’s phase 3 clinical trials included 300 patients in a randomized, placebo controlled environment conducted at 18 locations in the United States and 2 in Israel. A computerized Test of Variables of Attention, or TOVA, was used to determine the effectiveness of MDX for adult ADHD in phase 2b clinical trials, which recorded positive results. The drug showed an impressive statistically significant change in TOVA ADHD score. TOVA is also being used for the phase 3 trials and Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra Ltd, expects positive results again. In a press release published on July 14.
Currently, the most popular treatments for ADHD are stimulant drugs like Adderall or Ritalin. These drugs, while mostly effective, can be quite dangerous if frequently taken. Stimulant drugs may cause a wide range of side effects including cardiovascular complications, especially in adults. These side effects occur because of changes of various neurotransmitters in the brain caused by stimulants, which is why stimulants are controlled substances regulated by government agencies. Alcobra's MDX promises to be an effective non-stimulant treatment alternative. The company is also conducting separate phase 2b trials in pediatric ADHD and Fragile X Syndrome. The results from both trials should be reported by the end of the year.
If you held this stock since the beginning, you might be even. What a return on investment. Yes, I bought today, it is same low price as nearly 20 years ago. It is either making money in the next 12 months or going bust. I will see it to the end of 12 months, if no change I will sell out, if they did not go bust before.
YEP! Oncolytics Biotech, Inc. (ONCY) After Hours Trading
Of course they released news after hours, because they could not keep up the buy action if the market were open, or is that the sell action. Results show no meaningful long term survival, you get about 6 weeks, seems that is about all, the good news it won't kill you. See what happens when the market opens, I'd bet down or no change.
Dr. Brad Thompson , President and CEO of Oncolytics, will host a conference call and webcast with slide presentation on Tuesday September 16, 2014, at 4:30 p.m. MT (6:30 p.m. ET) to discuss in more depth the data from the randomized Phase 2 study in pancreatic cancer (NCI-8601). To access, the audio of the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live multimedia webcast will be available at the following
Who knows why options trade the way they do, they are all gamblers, might as well be in Vegas. I think the 20th looks good. They have the data, may depend on what positions they are holding.
biradamin .. I think they have all result now if you listened to yesterdays presentation, they are compiling the results now and I think they will e released bythe20th, as they indicated the results could be compiled quickly . That is my take
If you listen to the presentations the company believes failure is not an option. Phase 3 trials never fail when a phase 2 has success. Phase 2 was successful.
Take it up $1.05 and then take it down for a days loss. Anyone know how that can happen? I wonder if the impotent SEC watches such actions in the market of small caps?
What you said is correct, however they have to present the latest results to the FDA on Sept 30 to show they meet guidelines for forward to 2015. They need the FDA's blessing in order to apply for PDUFA in 2015. If FDA did not like what they saw from the latest trial, it likely would be over, however if they approve, it goes along way to final approval and sales in 2015.
Sentiment: Strong Buy